维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Jose A.Rodriguez"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Targeted therapies in cancer:where are we going?显示文摘SPECIAL ISSUE INTRODUCTION Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells.A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib,an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia.Over the last years,significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases,but also other protein families and cellular processes.Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies,such as lung cancer.The special issue on“Targeted cancer therapy”will include reviews and commentaries updating the clinical use of targeted agents in the treatment of different tumor types,and the mechanisms that underlie the action of drugs directed to different types of targets.The special issue will also include research articles presenting novel outstanding data on all aspects of targeted cancer therapy.All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.	Elisa Giovannetti Jose A.Rodriguez	2018	Cancer Drug Resistance2018，1，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费